AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2017
Dec 30, 2017
31289_dirs_2017-12-29_cd5ead1f-4ac9-4fd4-b3d0-05646fad9d25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-12-28
Reporting Person: HIGGINS JOHN L (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-28 | Common Stock | A | 9965 | $0.0 | Acquired | 151249 | Direct |
| 2017-12-28 | Common Stock | F | 5199 | $138.66 | Disposed | 146050 | Direct |
Footnotes
F1: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the three-year performance period ending December 31, 2017. On December 28, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.
F2: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs.